Do Surrogate Endpoints Better Correlate with Overall Survival in Studies That Did Not Allow for Crossover or Reported Balanced Postprogression Treatments? An Application in Advanced Non–Small Cell Lung Cancer

导出原文传递

翻译打印收藏纠错

作者： Mahmoud Hashim ^[1] ; Boris M. Pfeiffer ^[2] ; Robert Bartsch ^[3] ; Maarten Postma ; Bart Heeg

作者单位： University of Groningen, Groningen, The Netherlands ^[1] Merck KgaA, Darmstadt, Germany ^[2] Ingress-health, Health Economics and Real-World Evidence ^[3]

关键词 crossover non–small cell lung cancer overall survival surrogate endpoints validation

发布时间 2019-12-11

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

Value in health

2018年21卷1期

9-17页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Do Surrogate Endpoints Better Correlate with Overall Survival in Studies That Did Not Allow for Crossover or Reported Balanced Postprogression Treatments? An Application in Advanced Non–Small Cell Lung Cancer

Value in health

相似文献

Value in health

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Do Surrogate Endpoints Better Correlate with Overall Survival in Studies That Did Not Allow for Crossover or Reported Balanced Postprogression Treatments? An Application in Advanced Non–Small Cell Lung Cancer

Value in health

相似文献

Value in health

相关期刊

检索历史清除